The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Diabetes is a chronic, progressive disease that can be controlled with effective treatment. However, in many countries, people living with diabetes are not getting the treatment they need to stay healthy and alive.
MSF calls for ambitious targets for diagnosis, treatment and control of diabetes, in line with the 90-90-90 targets for HIV, and transparency on insulin pricing to ensure affordable access
Why is insulin, discovered almost 100 years ago, not readily available to people who need it? A combination of factors, including high prices, challenging storage requirements and complex treatment protocols, all contribute to ...
The WHO announced yesterday it is launching its ‘prequalification’ programme for ‘biosimilar’ human insulins*, in order to evaluate and help accelerate the quality approval of more human insulin sources.